Eli Lilly and Company (LLY) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↑
31.00
↓-13% vs avg
5yr avg: 35.82
30Y Low4.9·High44.6
P/FCF
↑
104.06
↓-78% vs avg
5yr avg: 479.16
30Y Low6.8·High107.6
P/B Ratio
↑
33.44
↓-14% vs avg
5yr avg: 38.95
30Y Low3.1·High48.9
ROE
↑
101.2%
↓+36% vs avg
5yr avg: 74.2%
30Y Low-20%·High145%
Debt/EBITDA
↓
1.36
↓-20% vs avg
5yr avg: 1.71
30Y Low0.7·High2.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LLY Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Eli Lilly and Company trades at 43.1x earnings, 32% below its 5-year average of 63.2x, sitting at the 78th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a premium of 94%. On a free-cash-flow basis, the stock trades at 104.1x P/FCF, 78% below the 5-year average of 479.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $933.7B | $965.1B | $697.9B | $526.5B | $347.6B | $263.4B | $161.5B | $125.8B | $119.6B | $88.9B | $81.0B |
| Enterprise Value | $969.0B | $1.00T | $728.3B | $548.9B | $361.8B | $276.5B | $174.4B | $139.3B | $122.6B | $96.0B | $86.7B |
| P/E Ratio → | 43.06 | 46.83 | 65.93 | 100.50 | 55.68 | 47.22 | 26.10 | 15.12 | 36.97 | — | 29.54 |
| P/S Ratio | 14.32 | 14.81 | 15.49 | 15.43 | 12.18 | 9.30 | 6.58 | 5.64 | 5.57 | 4.45 | 3.82 |
| P/B Ratio | 33.44 | 36.37 | 48.90 | 48.47 | 32.26 | 28.77 | 27.73 | 46.63 | 10.96 | 7.62 | 5.75 |
| P/FCF | 104.06 | 107.56 | 1684.61 | — | 75.56 | 48.89 | 36.13 | 36.13 | 47.73 | 25.74 | 21.54 |
| P/OCF | 55.53 | 57.40 | 79.15 | 124.18 | 45.82 | 35.76 | 24.85 | 26.02 | 21.65 | 15.82 | 16.69 |
P/E links to full P/E history page with 30-year chart
LLY EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Eli Lilly and Company's enterprise value stands at 31.0x EBITDA, 13% below its 5-year average of 35.8x. The Healthcare sector median is 14.0x, placing the stock at a 121% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.35 | 16.17 | 16.09 | 12.68 | 9.76 | 7.11 | 6.24 | 5.70 | 4.80 | 4.09 |
| EV / EBITDA | 31.00 | 32.00 | 37.80 | 44.58 | 35.55 | 29.16 | 20.44 | 19.26 | 16.06 | 16.50 | 16.15 |
| EV / EBIT | 32.63 | 37.93 | 54.11 | 77.97 | 50.68 | 42.57 | 22.99 | 24.59 | 31.25 | 37.93 | 24.36 |
| EV / FCF | — | 111.50 | 1757.93 | — | 78.64 | 51.32 | 39.02 | 40.00 | 48.91 | 27.80 | 23.06 |
LLY Profitability
Margins and return-on-capital ratios measuring operating efficiency
Eli Lilly and Company earns an operating margin of 45.6%. Operating margins have expanded from 31.6% to 45.6% over the past 3 years, signaling improving operational efficiency. Return on equity of 101.2% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 41.8% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 83.8% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating Margin | 45.6% | 45.6% | 38.9% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% |
| Net Profit Margin | 31.7% | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 101.2% | 101.2% | 84.3% | 48.4% | 62.7% | 74.5% | 145.3% | 122.3% | 28.6% | -1.6% | 19.1% |
| ROA | 21.6% | 21.6% | 14.8% | 9.2% | 12.7% | 11.7% | 14.4% | 20.0% | 7.3% | -0.5% | 7.4% |
| ROIC | 41.8% | 41.8% | 33.7% | 27.8% | 27.5% | 29.0% | 31.0% | 29.9% | 27.7% | 16.5% | 15.0% |
| ROCE | 46.6% | 46.6% | 40.2% | 31.2% | 26.2% | 23.4% | 23.4% | 20.2% | 19.3% | 14.6% | 14.0% |
LLY Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Eli Lilly and Company carries a Debt/EBITDA ratio of 1.4x, which is manageable (56% below the sector average of 3.1x). Net debt stands at $35.3B ($42.5B total debt minus $7.2B cash). Interest coverage of 33.2x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.60 | 1.60 | 2.36 | 2.32 | 1.51 | 1.84 | 2.85 | 5.86 | 0.94 | 1.17 | 0.73 |
| Debt / EBITDA | 1.36 | 1.36 | 1.75 | 2.05 | 1.60 | 1.78 | 1.94 | 2.19 | 1.35 | 2.35 | 1.92 |
| Net Debt / Equity | — | 1.33 | 2.13 | 2.06 | 1.32 | 1.43 | 2.22 | 4.99 | 0.27 | 0.61 | 0.41 |
| Net Debt / EBITDA | 1.13 | 1.13 | 1.58 | 1.82 | 1.39 | 1.38 | 1.52 | 1.86 | 0.39 | 1.22 | 1.07 |
| Debt / FCF | — | 3.94 | 73.32 | — | 3.08 | 2.43 | 2.89 | 3.87 | 1.19 | 2.06 | 1.52 |
| Interest Coverage | 33.16 | 33.16 | 17.24 | 14.49 | 21.53 | 19.12 | 21.11 | 14.15 | 16.18 | 11.24 | 19.22 |
LLY Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.58x means Eli Lilly and Company can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.19x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 0.94x to 1.58x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.58 | 1.58 | 1.15 | 0.94 | 1.05 | 1.23 | 1.40 | 1.16 | 1.73 | 1.32 | 1.37 |
| Quick Ratio | 1.19 | 1.19 | 0.89 | 0.73 | 0.80 | 0.97 | 1.08 | 0.89 | 1.47 | 1.01 | 1.05 |
| Cash Ratio | 0.21 | 0.21 | 0.12 | 0.11 | 0.13 | 0.26 | 0.29 | 0.21 | 0.62 | 0.55 | 0.55 |
| Asset Turnover | — | 0.58 | 0.57 | 0.53 | 0.58 | 0.58 | 0.53 | 0.57 | 0.49 | 0.44 | 0.55 |
| Inventory Turnover | 0.77 | 0.77 | 1.11 | 1.23 | 1.54 | 1.88 | 1.38 | 1.48 | 1.51 | 1.00 | 1.60 |
| Days Sales Outstanding | — | 112.87 | 107.58 | 121.25 | 109.45 | 104.75 | 103.06 | 90.62 | 98.10 | 96.16 | 81.98 |
LLY Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Eli Lilly and Company returns 1.0% to shareholders annually — split between a 0.6% dividend yield and 0.4% buyback yield. The payout ratio of 26.1% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 2.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.6% | 0.6% | 0.7% | 0.8% | 1.0% | 1.2% | 1.7% | 1.9% | 1.9% | 2.5% | 2.7% |
| Payout Ratio | 26.1% | 26.1% | 44.2% | 77.7% | 56.6% | 55.3% | 43.4% | 29.0% | 71.5% | — | 78.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | 2.1% | 1.5% | 1.0% | 1.8% | 2.1% | 3.8% | 6.6% | 2.7% | — | 3.4% |
| FCF Yield | 1.0% | 0.9% | 0.1% | — | 1.3% | 2.0% | 2.8% | 2.8% | 2.1% | 3.9% | 4.6% |
| Buyback Yield | 0.4% | 0.4% | 0.4% | 0.1% | 0.4% | 0.5% | 0.3% | 3.5% | 3.5% | 0.3% | 0.7% |
| Total Shareholder Yield | 1.0% | 1.0% | 1.0% | 0.9% | 1.4% | 1.6% | 2.0% | 5.4% | 5.4% | 2.8% | 3.4% |
| Shares Outstanding | — | $898M | $904M | $903M | $950M | $954M | $957M | $958M | $1.0B | $1.1B | $1.1B |
Peer Comparison
Compare LLY with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LLYYou | $934B | 43.1 | 31.0 | 104.1 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 NVO | $151B | 12.4 | 7.4 | 17.0 | 81.0% | 41.4% | 58.4% | 34.9% | 0.9 |
 PFE | $150B | 19.4 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $279B | 15.5 | 10.8 | 22.6 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 AZN | $281B | 27.7 | 15.7 | 23.9 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 BMY | $116B | 16.5 | 9.3 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 ABBV | $365B | 87.0 | 15.2 | 20.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $544B | 39.0 | 18.9 | 27.4 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 NVS | $278B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 AMGN | $178B | 23.2 | 14.1 | 22.0 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 BIIB | $28B | 21.4 | 11.3 | 13.6 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full LLY Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy LLY Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See LLY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LLY Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LLY vs NVO
Side-by-side business, growth, and profitability comparison vs Novo Nordisk A/S.
Start ComparisonLLY — Frequently Asked Questions
Quick answers to the most common questions about buying LLY stock.
What is Eli Lilly and Company's P/E ratio?
Eli Lilly and Company's current P/E ratio is 43.1x. The historical average is 32.4x. This places it at the 78th percentile of its historical range.
What is Eli Lilly and Company's EV/EBITDA?
Eli Lilly and Company's current EV/EBITDA is 31.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.1x.
What is Eli Lilly and Company's ROE?
Eli Lilly and Company's return on equity (ROE) is 101.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 41.8%.
Is LLY stock overvalued?
Based on historical data, Eli Lilly and Company is trading at a P/E of 43.1x. This is at the 78th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Eli Lilly and Company's dividend yield?
Eli Lilly and Company's current dividend yield is 0.61% with a payout ratio of 26.1%.
What are Eli Lilly and Company's profit margins?
Eli Lilly and Company has 83.8% gross margin and 45.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Eli Lilly and Company have?
Eli Lilly and Company's Debt/EBITDA ratio is 1.4x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.